KPV Legal Status and the FDA 503A Compounding Framework

The short version

Here is KPV legal status in plain terms. KPV is not an FDA-approved drug for anything. It is sold for laboratory research only, not as a medicine or supplement. But its status is in motion: the FDA has scheduled KPV for discussion at a public advisory-committee meeting on July 23-24, 2026, where experts will consider whether it should be added to a special list that would let compounding pharmacies use it. That meeting is a discussion, not a decision — nothing has changed yet, and no outcome is guaranteed. Below is how the framework works and where KPV sits today, cited to the FDA.

The current fact: KPV is not FDA-approved, and is scheduled for evaluation

KPV — the C-terminal tripeptide (lysine-proline-valine) of alpha-melanocyte-stimulating hormone — is a research peptide and is not an FDA-approved drug for any indication ^[17]. Under the U.S. Federal Food, Drug, and Cosmetic Act, a bulk drug substance may be used in 503A pharmacy compounding only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list; substances not yet on that list are evaluated by FDA through a public nomination process informed by the Pharmacy Compounding Advisory Committee (PCAC) ^[16].

KPV is one of the bulk drug substances FDA has scheduled for PCAC evaluation ^[17]. Being under evaluation is not the same as being on the bulks list, and it is not the same as being approved for compounding ^[16]. KPV's present-tense status is: research peptide, not FDA-approved, scheduled for PCAC evaluation ^[17].

For accuracy, this page does not assign KPV a numbered 503A "Category." The audited FDA reference behind this site states detailed category placements only for certain other peptides; it does not place KPV in Category 1, 2, or 3, so none is stated or implied here ^[16].

Under active review: the July 23-24, 2026 PCAC meeting

The momentum is real and it is documented. KPV is individually named on the published agenda of the FDA Pharmacy Compounding Advisory Committee meeting scheduled for July 23-24, 2026, as a bulk drug substance "being considered for inclusion on the 503A Bulks List" — evaluated in both its free base and acetate forms ^[17]. The same agenda also lists BPC-157, TB-500, and MOTs-C ^[17].

What that listing is, precisely: a scheduled evaluation and discussion. It is not a listing decision, not a reclassification, and not a change in KPV's current status ^[17]. A PCAC discussion is advisory; inclusion on a final 503A bulks list is decided by FDA rulemaking informed by the committee, and being discussed by PCAC is a step in evaluation, not a final listing decision ^[16]. No outcome of the July 2026 meeting should be assumed, and none is asserted here ^[17].

Separately, some commercial and clinic sources have circulated claims of an early-2026 reclassification of peptides, or of specific dated removals from a safety-risk list. Those claims could not be confirmed from an authoritative FDA source and are not treated as fact on this page ^[16]. The documented point is narrow and forward-leaning: KPV is on a scheduled FDA agenda, and access may expand if FDA acts — but it has not acted yet ^[17].

How the 503A and 503B framework works

Two sections of the Federal Food, Drug, and Cosmetic Act govern compounding. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies, federal facilities, and licensed physicians, generally pursuant to a valid prescription for an individual patient ^[16]. Section 503B covers registered "outsourcing facilities" that may compound larger batches under cGMP-style oversight and FDA registration and inspection ^[16].

The ingredient rule is the gate. A compounder may use a bulk drug substance — an active pharmaceutical ingredient used as a starting material, rather than an FDA-approved finished drug — only if that substance has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on the relevant FDA bulks list ^[16]. Substances not yet on a bulks list are evaluated by FDA through the public nomination process, with input from PCAC ^[16]. FDA approval of a finished drug is a separate question from whether a bulk substance may be used in compounding; KPV is not an FDA-approved drug ^[16][17].

How legally compounded peptide access works, in general

In the U.S., a legally compounded medication is prepared only after an individual patient is evaluated by an appropriately licensed prescriber who determines a compounded preparation is appropriate and issues a valid, patient-specific prescription ^[16]. The preparation is then made either by a state-licensed 503A compounding pharmacy (patient-specific) or, for larger volumes, by an FDA-registered 503B outsourcing facility ^[16].

Telehealth can serve as the front-end channel through which a patient is evaluated and a prescription is issued, but it does not change which substances are eligible to be compounded, and it does not remove the requirement for a legitimate prescriber-patient relationship and a valid prescription ^[16]. The ingredient-eligibility caveat governs everything downstream: a compounder may use a requested active ingredient only if that ingredient is eligible under the 503A/503B bulk-substance rules, and a substance FDA has flagged for significant safety risks (a Category 2 substance) is not eligible for routine 503A compounding while that status stands ^[16].

This is general information about the regulatory landscape — not medical or legal advice, and not an offer to sell or supply any substance ^[16]. It names no pharmacy, clinic, vendor, or telehealth provider, gives no dosing, and describes no way to obtain any substance outside the lawful framework ^[16].

Is KPV legal?

KPV is sold by chemical suppliers for laboratory research use only and is not an approved drug or dietary supplement in any major jurisdiction ^[17]. It is not FDA-approved for human use, and it is scheduled for FDA PCAC evaluation rather than already listed for compounding ^[16][17].

What is the FDA 503A status of KPV?

KPV is not FDA-approved and has no recognized USP/NF monograph; under the 503A framework, a bulk substance must have a monograph, be a component of an approved drug, or be on the FDA bulks list to be compounded ^[16]. KPV is none of these today — it is scheduled for PCAC evaluation for possible inclusion on the 503A bulks list at the July 23-24, 2026 meeting, which is a discussion, not a listing ^[17]. This page assigns KPV no numbered 503A category, consistent with the audited FDA reference ^[16].

Can you get KPV from a compounding pharmacy?

KPV has no approved drug status, and a 503A pharmacy may compound with a bulk substance only when it has a USP/NF monograph, is part of an approved drug, or is on the FDA bulks list ^[16]. KPV does not currently meet those conditions and is under FDA evaluation, so access is research-only as that status stands ^[16][17]. The lawful compounding pathway in general is: licensed-prescriber evaluation (telehealth may be the front-end channel), a valid patient-specific prescription, then a 503A pharmacy or 503B outsourcing facility — subject to ingredient eligibility ^[16].